{"title":"Management of ventricular tachycardia in patients with advanced heart failure.","authors":"Ioan Liuba, Jakub Sroubek, Pasquale Santangeli","doi":"10.1016/j.pcad.2025.04.006","DOIUrl":null,"url":null,"abstract":"<p><p>Ventricular arrhythmias (VAs) are highly prevalent in patients with advanced heart failure (AHF), a condition characterized by severe signs and symptoms despite conventional HF therapy. The management of VAs in this setting remains challenging. Antiarrhythmic drug therapy options are limited and only amiodarone has demonstrated effectiveness in suppressing VA, albeit this agent is associated with a substantial risk of cardiac and noncardiac adverse effects. Catheter ablation is effective for the reduction of VAs in patients with AHF. Identification of patients at high risk for periprocedural hemodynamic decompensation has important implications in terms of procedural planning and improving patient safety and procedural outcomes. Herein, we review the current state of scientific evidence for the management of VA in patients with AHF.</p>","PeriodicalId":94178,"journal":{"name":"Progress in cardiovascular diseases","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in cardiovascular diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.pcad.2025.04.006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Ventricular arrhythmias (VAs) are highly prevalent in patients with advanced heart failure (AHF), a condition characterized by severe signs and symptoms despite conventional HF therapy. The management of VAs in this setting remains challenging. Antiarrhythmic drug therapy options are limited and only amiodarone has demonstrated effectiveness in suppressing VA, albeit this agent is associated with a substantial risk of cardiac and noncardiac adverse effects. Catheter ablation is effective for the reduction of VAs in patients with AHF. Identification of patients at high risk for periprocedural hemodynamic decompensation has important implications in terms of procedural planning and improving patient safety and procedural outcomes. Herein, we review the current state of scientific evidence for the management of VA in patients with AHF.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
